1. Home
  2. BNKK vs BLRX Comparison

BNKK vs BLRX Comparison

Compare BNKK & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BNKK

Bonk Inc.

HOLD

Current Price

$1.28

Market Cap

13.0M

ML Signal

HOLD

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

HOLD

Current Price

$2.95

Market Cap

12.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNKK
BLRX
Founded
2018
2003
Country
United States
Israel
Employees
10
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.0M
12.6M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
BNKK
BLRX
Price
$1.28
$2.95
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$19.00
AVG Volume (30 Days)
143.4K
14.1K
Earning Date
05-14-2026
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$2.15
52 Week High
$7.19
$4.75

Technical Indicators

Market Signals
Indicator
BNKK
BLRX
Relative Strength Index (RSI) 36.07 43.07
Support Level $0.12 $2.65
Resistance Level $1.66 $3.11
Average True Range (ATR) 0.09 0.20
MACD 0.01 -0.03
Stochastic Oscillator 24.26 37.97

Price Performance

Historical Comparison
BNKK
BLRX

About BNKK Bonk Inc.

Bonk Inc provides over-the-counter products and consumer products in the United States. The company offers Safety Shot Beverage, an over-the-counter drink that lowers blood alcohol content. It sells its products through direct customers, distributors, retailers, and e-commerce websites. The company generates revenue through various channels, its primary sales include nostingz suncare products which are sold through e-commerce platforms, licensing revenues from Photocil and sales of the Safety Shot Beverage. The company has two reportable segments: the dietary and energy beverage business and digital assets, consisting of investing for growth in the appreciation of the asset. It derives the majority of the revenue from the dietary and energy beverage segment.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: